L&T infrastructure, a well-known player in the infrastructure sector has bagged orders from prestigious clients for two of its businesses.

Mrs Bectors Food Specialities, one of the leading companies in the premium & mid-premium biscuits segment, is hitting the primary capital market with its IPO. Read on to find out if you should subscribe to the issue. 

Sterlite Technologies: The company has made a number of key leadership appointments to expand its capabilities to offer end-to-end advanced solutions for digital networks, and drive its next phase of growth.

Even though the markets ended in green on Monday, volatility was the hallmark of the session as India VIX rose by 3.25 to 19.40. Further, multiple indecisive candle formations on the daily chart signalled that the dominant bulls are witnessing a slowdown in their pace of ascending.

Overall, Nifty seems to move slowly and gradually in the northward directions but with the formation of multiple indecisive candles in the last couple of trading sessions, it clearly indicates that the momentum is dwindling and if the indecisive bars get a confirmation (by closing below the prior bar low), the bears would smell the blood.

Ramco Systems on Monday stated that it has signed four agreements worth multi-million dollars.

On Monday, Burger King gained by around 131 per cent, touching its high of Rs 18 per share on BSE on the listing debut day. 

Markets ended close to record highs as Sensex gained by 154.45 points or by 0.34 per cent to settle at 46,253.46 levels while Nifty rose by 44.30 points or 0.33 per cent to close at 13,558.15 levels.

Franklin India Focused Equity fund is a focussed multi-cap fund offering from Franklin Templeton AMC India. Read on to find out more.

Cipla has settled its patent litigation with Celgene over the blockbuster cancer drug Revlimid. Celgene Corporation, a subsidiary of Bristol Myers Squibb, has agreed to provide Cipla with a licence to Celgene’s required patents. Cipla can then sell or manufacture certain volume-limited amounts of generic Lenalidomide in the United States sometime after March 2022.